Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Avalon GloboCare ( (ALBT) ) has shared an update.
On January 21, 2026, Avalon GloboCare Corp. and YOOV Group Holding Limited mutually terminated their March 7, 2025 merger agreement, waiving any termination fees or expense reimbursements and providing each other with mutual releases of claims, a three-year mutual non-disparagement covenant, and capped indemnification obligations, thereby formally closing out the previously planned transaction. On January 22, 2026, Avalon announced that its subsidiary, Avalon Quantum AI LLC, had filed a U.S. provisional patent application on January 16, 2026 for an evidence-constrained, audience-adaptive generative AI system designed to produce automated video commentary with embedded source traceability and audit trails, targeting compliance-ready use in regulated, high-value content markets such as financial commentary, news, sports analysis, and brand-sensitive media.
More about Avalon GloboCare
Avalon GloboCare Corp. (NASDAQ: ALBT) is a diversified company focused on precision diagnostic consumer products, advancement of intellectual property in cellular therapy, and generative artificial intelligence publishing and software. The company currently markets the KetoAir™ breathalyzer, an FDA-registered Class I medical device, is pursuing additional diagnostic applications for its breathalyzer technology, continues to build its patent portfolio, and also owns and operates commercial real estate.
Average Trading Volume: 206,120
Technical Sentiment Signal: Sell
Current Market Cap: $5.01M
See more insights into ALBT stock on TipRanks’ Stock Analysis page.